Loading...Loading...FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma company Cybin Inc. CYBN announced that the Food and Drug Administration has granted Breakthrough Therapy designation to CYB003, its proprietary deuterated psilocybin analog targeting the adjunctive treatment of Major Depressive Disorder (MDD.) It makes the group of psychedelic-based treatments for mental health conditions that have in recent years received such status granted by the U.S.

正在加载。。。正在加载。。。美国食品和药物管理局（FDA）授予Cybin重大抑郁症裸盖菇素治疗突破性治疗地位，该公司宣布积极的临床数据和加拿大1.5亿美元的私人配售临床阶段迷幻药生物制药公司Cybin Inc.CYBN宣布，美国食品和药物管理局（FDA）已授予CYB003突破性治疗称号，CYB003是其专有的氘代裸盖菇素类似物，用于辅助治疗重度抑郁症（MDD）。它使近年来获得美国授予此类地位的一组以迷幻药为基础的心理健康治疗方法。

federal agency five therapies total: Cybin's, MindMed's MNMD LSD-derived treatment for Generalized Anxiety Disorder, MAPS’ MDMA-assisted therapy for PTSD treatment, Compass Pathways’ CMPS psilocybin therapy targeting Treatment-Resistant Depression (TRD,) and Usona Institute's psilocybin therapy for MDD as well.

联邦机构共有五种疗法：Cybin，MindMed的MNMD LSD衍生治疗广泛性焦虑症，MAPS的MDMA辅助治疗PTSD治疗，Compass Pathways的CMPS psilocybin治疗靶向治疗抵抗性抑郁症（TRD），以及Usona研究所的psilocybin治疗MDD。

READ MORE.MindMed Receives FDA ‘Breakthrough Therapy’ Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials And Expected $175M ProceedsMind Medicine (MindMed) announced that the FDA has granted the “breakthrough therapy” designation to its MM120 (lysergide d-tartrate) program for the treatment of Generalized Anxiety Disorder (GAD). The company stated that, based on the significant unmet medical need in the treatment of GAD, especially in patients who do not respond to or tolerate currently available medications, this news as well as initial clinical data from other research, the FDA has designated MM120 for GAD as a breakthrough therapy.

阅读更多。MindMed获得了FDA关于LSD作为焦虑治疗的“突破疗法”指定，分享了相关临床试验的积极结果，并预计将获得1.75亿美元的ProceedsMind Medicine（MindMed）宣布，FDA已授予其MM120（麦角苷d-酒石酸盐）治疗广泛性焦虑症（GAD）的“突破疗法”指定。该公司表示，基于GAD治疗中显着未满足的医疗需求，特别是对目前可用药物无反应或耐受的患者，这一消息以及其他研究的初步临床数据，FDA已将MM120指定为GAD作为突破性治疗。

READ MORE.Shortly following the news, the company announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 each. .

阅读更多。消息发布后不久，该公司宣布承销1666667股普通股，每股无面值，每股发行价格为6美元。

Total gross proceeds, from the underwritten offering and the concurrent private placement are expected to be around $175 million. READ MORE.Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use DisorderClinical-stage neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, a novel, reportedly cardiac-safe ibogaine analog for the treatment of substance use disorders. As recently reported in the York Times, the plant-derived psychoactive compound ibogaine holds accumulated data from trials and case reports that point to its robust efficacy as a treatment for substance use disorders.

包销发行和同期私募的总收益预计约为1.75亿美元。阅读更多。美联储机构向Gilgamesh拨款1400万美元，用于心脏安全的伊博加因类似物靶向阿片类药物使用障碍临床阶段神经科学公司Gilgamesh Pharmaceuticals已获得美国国家药物滥用研究所（NIDA）的1400万美元多年拨款，用于开发GM-3009，这是一种新型的，据报道用于治疗药物使用障碍的心脏安全伊博加因类似物。正如《约克时报》最近报道的那样，植物衍生的精神活性化合物伊博加因拥有来自试验和病例报告的累积数据，这些数据表明其作为治疗物质使用障碍的强大功效。

READ MORE.Loading...Loading...Indiana Governor Signs Health Bill Including State Funds For Psilocybin ResearchIndiana Gov. Eric J. Holcomb (R) acted swiftly on the passing of a health bill, which includes provisions to fund clinical research trials into psilocybin. Sent by the state legislators to his desk on March 12, the governor officially signed the proposal into law the following day, March 13.The bill, HB 1259, with final amendments adding the psychedelics language – originally SB 139 passed the Senate and the House’s Public Health committee – received the green light from both state chambers on March 12.

阅读更多。正在加载。。。正在加载。。。印第安纳州州长签署健康法案，包括为裸盖菇素研究提供州资金。印第安纳州州长埃里克·J·霍尔科姆（右）迅速采取行动，通过了一项健康法案，其中包括资助裸盖菇素临床研究试验的规定。3月12日，州议员将该法案发送到他的办公桌上，州长于第二天（3月13日）正式签署该提案，使其成为法律。该法案HB 1259，最终修正案增加了迷幻药语言，最初是SB 139，于3月12日在参议院和众议院公共卫生委员会获得通过。

READ MORE.The Milestone Round.

阅读更多。里程碑回合。

Psyence Biomedical PBM will undertake psilocybin clinical trials for palliative care in Australia.

Psyence Biomedical PBM将在澳大利亚进行psilocybin姑息治疗临床试验。

Denver to become first US city to train first responders in psychedelics crisis intervention.

丹佛将成为美国第一个培训迷幻剂危机干预急救人员的城市。

Truffles to market: Red Light Holland TRUFF wants to develop psilocybin API at scale.

块菌上市：红光荷兰块菌希望大规模开发裸盖菇素API。

Podcast: Clearmind’s CMND non-hallucinogenic psychoactive molecule could become a solution for addictive behaviors.

播客：Clearmind的CMND非致幻剂精神活性分子可能成为成瘾行为的解决方案。

From isolation to integration: the case for group ketamine therapy with Zappy Zapolin.

从隔离到整合：用扎比·扎波林进行氯胺酮集体治疗的情况。

CEO of a leading Canadian cryptocurrency business is excited about the future of the market.

加拿大领先加密货币业务的首席执行官对市场的未来感到兴奋。

Michigan cops bust one of the largest illegal weed grow operations to date.

密歇根州警方破获了迄今为止最大的非法杂草种植行动之一。

What’s going on with Psyence Biomedical stock? (March 8, 2024)

Psyence Biomedical股票怎么样了？（2024年3月8日）

Psychedelics 2024: Veterans blessing, mental health paradigm shift, providers training, ketamine-MDMA bonds & more.

迷幻药2024：退伍军人祝福，心理健康范式转变，提供者培训，氯胺酮MDMA债券等。

Why do magic mushrooms bruise blue? Science solves the mystery.

为什么神奇蘑菇会擦伤蓝色？科学解决了这个谜。

See Also: Prior Edition Of ‘Psyched'Psychedelics ETF’s Weekly PerformanceAdvisorShares Psychedelics ETF PSIL opened Monday, March 18 at $1.50, following prior openings at $1.65, $1.58, and $1.46 (March 11, 4 and Feb. 26, respectively.)On Friday, March 15 it closed at $1.53, following prior closings at $1.64, $1.57 and $1.41 (March 8, 1 and Feb.

另请参见：《迷幻迷幻药》ETF前一版的每周表现维索尔股份迷幻药ETF PSIL于3月18日周一开盘，价格为1.50美元，此前开盘价分别为1.65美元、1.58美元和1.46美元（分别为3月11日、4日和2月26日）。3月15日，周五收盘价为1.53美元，此前收盘价分别为1.64美元、1.57美元和1.41美元（3月8日、1日和2月26日）。

23, respectively.)Last week’s highest was $1.65, at Tuesday, March 12 closing. Prior weeks' highests were $1.78, $1.57 and $1.52.Week’s lowest was $1.46 at several points during the week. Prior weeks' lowests were $1.44, $1.43 and $1.41.Highest Trading Psychedelics Stocks Friday, March 15 Close.

分别为23。）上周的最高点是3月12日星期二收盘时的1.65美元。前几周的最高点是1.78美元、1.57美元和1.52美元。本周的最低点是1.46美元。前几周的最低价格分别为1.44美元、1.43美元和1.41美元。迷幻药类股的最高交易价格为3月15日周五收盘。

GH Research GHRS closed at $10.91, sustaining the upper trend as per prior weekly closings at $8.08, $8.50 and $7.51 (March 8, 1 and Feb. 23, respectively.)

GH Research GHRS收盘价为10.91美元，维持了之前每周收盘价为8.08美元、8.50美元和7.51美元的上涨趋势（分别为3月8日、1日和2月23日）

COMPASS Pathways closed at $9.90, down from prior closings at $10.88, $11.47 and $10.20.

COMPASS Pathways收盘价为9.90美元，低于之前的收盘价10.88美元、11.47美元和10.20美元。

Mind Medicine (MindMed) closed at $9.10, still jumping as per prior closings at $9.10, slightly behind the immediate prior week's closing at $9.50 yet still way high as from two and three weeks past closings at $6.21 and $4.91.

Mind Medicine（MindMed）收盘价为9.10美元，与之前收盘价9.10美元相比仍有所上涨，略低于前一周收盘价9.50美元，但仍远高于前两周和三周收盘价6.21美元和4.91美元。

Incannex Healthcare IXHL closed at $3.25, dropping from prior closings at $4.20, $5.37 and $4.84.

Incanex Healthcare IXHL收于3.25美元，较之前的收盘价4.20美元、5.37美元和4.84美元有所下降。

Silo Pharma SILO closed at $1.84, still up from prior closings at $1.61, $1.59 and $1.57.

思洛制药（Silo Pharma）思洛（Silo）收盘价为1.84美元，仍高于之前的收盘价1.61美元、1.59美元和1.57美元。

Atai Life Sciences ATAI closed at $1.75, also dropping from prior weekly closings at $2.11, $2.14 and $1.83.

Atai Life Sciences Atai收于1.75美元，也低于之前的每周收盘价2.11美元、2.14美元和1.83美元。

Bright Minds Biosciences DRUG closed at $1.31, still within the decreasing trend as per prior closings at $1.58, $1.76 and $1.88.

Bright Minds Biosciences药品收盘价为1.31美元，根据之前的收盘价1.58美元、1.76美元和1.88美元，仍处于下降趋势。

Clearmind Medicine CMND closed at $1.27, also still falling from prior closings at $1.38, $1.60 and $1.81.

Clearmind Medicine CMND收于1.27美元，也仍低于之前的收盘价1.38美元、1.60美元和1.81美元。

Lucy Scientific LSDI closed at $1.25, following closings at $1.70, $1.91 and $2.42.

Lucy Scientific LSDI收盘价为1.25美元，收盘价分别为1.70美元、1.91美元和2.42美元。

Enveric Biosciences ENVB closed at $1.07, following closings at $1.46, $1.62 and $0.95.

Enveric Biosciences ENVB收于1.07美元，收盘价分别为1.46美元、1.62美元和0.95美元。

Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!Now Read Psychedelics Headlines: Substitution Survey, Frank Herbert’s Magic Mushrooms, Celestial Plans And News ReviewLoading...Loading....

以上股票交易数字根据Benzinga Pro，我们提供您所需的所有信息流平台，帮助您更明智地投资-欢迎加入我们，亲自查看！现在阅读迷幻药标题：替代调查，弗兰克·赫伯特的神奇蘑菇，天体计划和新闻评论加载。。。正在加载。。。。